Gilead Sciences Rallies Off Epclusa Approval

Gilead Sciences

shares are trading higher by $2.63 at $80.88 in Tuesday's session. The catalyst for the rally is approval of Epclusa for the treatment of Chronic Hepatitis C. The issue made a new 52 week at $$77.92 in Monday's session. After a higher open, it retreated only $0.22 to $79.45 before ripping to $81.55. Since making that high is has fallen back under $81 and is attempting to mount another rally.